Progenics kept at sector perform by RBC

Progenics Pharmaceuticals, Inc. was kept at its sector perform, above average risk, by RBC Capital Markets analyst Michael Yee on news of the company's third-quarter results and expected news flow throughout the next year. Revenue of $18 million was generally in line with the analyst's estimate, while the net loss of $3 million missed the analyst's break-even forecast. Shares of the Tarrytown, N.Y.-based pharmaceutical company were up $1.98, or 7.29%, at $29.15. (Nasdaq: PGNX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.